These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36647478)

  • 1. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
    Ma Y; Pan H; Liu Y; Zhang Y; Hong S; Huang J; Weng S; Yang Y; Fang W; Huang Y; Xiao S; Wang T; Ding L; Cui L; Zhang L; Zhao H
    J Thorac Dis; 2022 Dec; 14(12):4751-4762. PubMed ID: 36647478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
    Xing P; Zhao Q; Zhang L; Wang H; Huang D; Hu P; Sun Y; Shi Y
    BMC Med; 2022 Nov; 20(1):453. PubMed ID: 36424628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
    Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
    Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
    [No Abstract]   [Full Text] [Related]  

  • 4. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
    JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
    Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
    Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
    Ma Y; Zhao H; Xue J; Liu L; Yang N; Zhang Y; Yang H; Hong S; Xiong Y; Zhang Z; Zeng L; Pan H; Zhou C; Zhang Y; Wang X; Han X; Wan X; Shao Y; Liu J; Yang Y; Huang Y; Zhao Y; Fang W; Li S; Zhang L
    Eur J Cancer; 2022 Sep; 173():238-249. PubMed ID: 35940055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
    Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
    Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
    J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
    Shi Y; Chen J; Zhang H; Zhang Z; Zhang Y; Wang Z; Zhang S; Zhao J; Liu C; Wang X; Zhao Y; Hu C; Yang L; Hao X; Wang L; Liu Y; Yu Y; Zhao J; Wang M; Zhang L; Sun S; Hu Y; Gu K; Hang X; Shan J; Zhang Y; Tan B; Yang W; Yang R; Si M; Geng H; Li H; Kang X
    BMC Med; 2023 Feb; 21(1):72. PubMed ID: 36829154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Santoro A; Su WC; Navarro A; Simonelli M; Ch Yang J; Ardizzoni A; Barlesi F; Hyoung Kang J; DiDominick S; Abdelhady A; Chen X; Stammberger U; Felip E
    Lung Cancer; 2022 Apr; 166():170-177. PubMed ID: 35298959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Wu YL; Shi Y; Tan DSW; Xiaoqing L; Cheng Y; Zhou J; An TT; Lu Y; Zhu B; Bai C; Passos VQ; Lau YY; Xun L; Zhang L
    Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.
    Shi Y; Hu X; Li X; Gong C; Wang K; Li Y; Zhang S; Luo Y; Wang P; Jiang L; Meng X; Dong X; Wang H; Yang R; Mei Q; Liu B; Yang L; Sun Y
    J Thorac Oncol; 2024 Jun; 19(6):898-911. PubMed ID: 38295954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.